CorMedix SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCorMedix Announces FDA Acceptance with Priority Review of REZZAYO sNDA for Prophylaxis of Invasive Fungal Disease; PDUFA Date Set for Q1 2027
Results of operations and financial condition · Financial statements and exhibits
Other events · Financial statements and exhibits